The Delhi High Court has stated that if an opponent misses the opportunity to file evidence in the form of an affidavit along with its opposition notice, it cannot file evidence when filing a rejoinder. The judgment underlines the intricacies related to post-grant opposition requirements and emphasises how critical it is to obey these to the letter.
As there is no AI regulation or precedent yet in Turkey, the question of AI inventorship is a key point of contention. Some argue that AI should be considered a legal entity, while others argue that the country follow Roman law principles.
During a recent Washington DC event, SEP holders and standards implementers clashed about the European Commission’s draft proposal – and how the US should respond
It’s a win for the patent owner seeking to reveal who is behind the IPR petitioner, and may deliver estoppel benefits in underlying district court litigation
17 February 2023
Germany ratifies agreement, Sunrise Period to start on 1 March
17 February 2023
IAM’s latest panel report surveyed sentiment of senior in-house and private practice patent professionals across a range of topics
16 February 2023
The Senate Judicial Committee has advanced several IP bills targeting life sciences rights owners
13 February 2023
Alexander Haertel talks about the Industry Patent Quality Charter, the UPC and German injunctions in an exclusive IAM interview
09 February 2023
From the archives: Lord Kitchin's in-depth interview with IAM
03 February 2023
For companies, policy makers and service providers, the growing importance of know-how as a quantifiable asset presents dangers and opportunities
02 February 2023
President can now pick out foreign entities and subject them to a series of sanctions
01 February 2023
The onus of identifying known substances in pharmaceutical patent applications is on the Indian Patent Office, according to a new ruling, which provides fresh clarity for prospective applicants.
01 February 2023
With Amgen’s biosimilar finally set to launch in the US, IAM looks back on arguably the most interesting set of pharma patent disputes in recent years
30 January 2023
Unlock unlimited access to all IAM content
